221 related articles for article (PubMed ID: 31446075)
1. New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling.
Tomas A; Jones B; Leech C
J Mol Biol; 2020 Mar; 432(5):1347-1366. PubMed ID: 31446075
[TBL] [Abstract][Full Text] [Related]
2. A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.
Buenaventura T; Kanda N; Douzenis PC; Jones B; Bloom SR; Chabosseau P; Corrêa IR; Bosco D; Piemonti L; Marchetti P; Johnson PR; Shapiro AMJ; Rutter GA; Tomas A
Diabetes; 2018 Mar; 67(3):385-399. PubMed ID: 29284659
[TBL] [Abstract][Full Text] [Related]
3. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.
Zhang M; Robitaille M; Showalter AD; Huang X; Liu Y; Bhattacharjee A; Willard FS; Han J; Froese S; Wei L; Gaisano HY; Angers S; Sloop KW; Dai FF; Wheeler MB
Mol Cell Proteomics; 2014 Nov; 13(11):3049-62. PubMed ID: 25044020
[TBL] [Abstract][Full Text] [Related]
5. Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
Koole C; Savage EE; Christopoulos A; Miller LJ; Sexton PM; Wootten D
Mol Endocrinol; 2013 Aug; 27(8):1234-44. PubMed ID: 23864649
[TBL] [Abstract][Full Text] [Related]
6. Control of insulin secretion by GLP-1.
Jones B; Bloom SR; Buenaventura T; Tomas A; Rutter GA
Peptides; 2018 Feb; 100():75-84. PubMed ID: 29412835
[TBL] [Abstract][Full Text] [Related]
7. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
8. Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells.
Buenaventura T; Bitsi S; Laughlin WE; Burgoyne T; Lyu Z; Oqua AI; Norman H; McGlone ER; Klymchenko AS; Corrêa IR; Walker A; Inoue A; Hanyaloglu A; Grimes J; Koszegi Z; Calebiro D; Rutter GA; Bloom SR; Jones B; Tomas A
PLoS Biol; 2019 Aug; 17(8):e3000097. PubMed ID: 31430273
[TBL] [Abstract][Full Text] [Related]
9. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
11. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.
Leech CA; Dzhura I; Chepurny OG; Kang G; Schwede F; Genieser HG; Holz GG
Prog Biophys Mol Biol; 2011 Nov; 107(2):236-47. PubMed ID: 21782840
[TBL] [Abstract][Full Text] [Related]
12. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
Nakane A; Gotoh Y; Ichihara J; Nagata H
Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.
Hou Y; Ernst SA; Heidenreich K; Williams JA
Am J Physiol Gastrointest Liver Physiol; 2016 Jan; 310(1):G26-33. PubMed ID: 26542397
[TBL] [Abstract][Full Text] [Related]
15. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.
Ma X; Guan Y; Hua X
J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
18. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells.
Marzook A; Tomas A; Jones B
Front Endocrinol (Lausanne); 2021; 12():678055. PubMed ID: 34040588
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
[TBL] [Abstract][Full Text] [Related]
20. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
